BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature�s chemistry, today announced that it will open two new drug discovery and development facilities to support its ongoing efforts to advance novel small molecule drugs.

Enveda is building out an advanced drug discovery and development center in the heart of Boulder, Colo. The 60,000-square-foot facility will significantly expand Enveda�s capacity to build a high-resolution chemical map of the natural world and identify new high-potential drug leads from it.

The company will also open a lead optimization laboratory in Genome Valley, Hyderabad�the �Life Science Capital of India,� which is home to more than 200 life science and pharmaceutical companies including Novartis and Lonza. Enveda�s 24,000-square-foot space there will bolster the company�s growing workforce in India and enable it to more efficiently optimize lead compounds to identify clinical drug candidates.

�In just two years, Enveda has developed a technology platform that breaks the bottleneck to finding medicines in nature�s chemistry�identifying the structure of each natural chemical and rapidly linking them to biological activity without needing to isolate individual compounds,� said Viswa Colluru, Ph.D., CEO and founder of Enveda. �Our two new facilities, housing the very best people and technology, will significantly extend and accelerate our ability to identify, optimize and advance unique small molecule drugs.�

Enveda expects to complete the development of the Boulder facility during the first quarter of 2023. The new advanced drug and development center will house:

• Nuclear magnetic resonance machines and the world�s most advanced mass spectrometry instruments to support Enveda�s work to identify, profile and understand the chemical basis of the natural world.
• A metabolomics laboratory that allows the company to expand its identification of small molecules.
• A high-throughput screening laboratory to test the effect of the newly discovered chemistry.
• A synthetic chemistry laboratory to derive new medicines on the basis of those molecules.
• One of the largest, most powerful and productive chemical libraries.

The Genome Valley laboratory will house imaging instruments, automated liquid handlers, and analysis software, among other state-of-the-art synthetic chemistry technologies used in the lead optimization cycle. The company expects to move into the new laboratory by the end of 2022. Enveda can expand its space in Hyderabad to accommodate nearly triple its current workforce.

�Our continued progress and success will only be made with Enveda�s most valuable asset�our people,� Dr. Colluru said. �They�re a big reason why we�re investing in our new facilities. We want to continue to create a world-class employee experience that enables our team to deliver hope to every patient.�

To reach its goals, Enveda is aggressively expanding its team across biology, chemistry, data science, engineering, and business development with plans to rapidly grow its employee base in the coming year. Enveda is expected to fill multiple new positions remotely in the United States and in India. More information on open positions can be found at https://www.envedabio.com/careers/

About Enveda Biosciences

Enveda Biosciences is a leading biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda�s platform is the world�s most advanced drug discovery search engine for the almost limitless expanse of nature�s unknown chemistry, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrough technology, Enveda�s team includes seasoned drug hunters with decades of experience in the pharmaceutical industry working alongside world-leading data scientists. For more information on Enveda, visit envedabio.com.

Contacts

CG Life

Lauren Stredler

[email protected]
847-271-6891

Enveda Biosciences

Rod Hise

[email protected]
608-770-7850